Hims & Hers Health, Inc. (HIMS) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Drug Manufacturers - Specialty & Generic
Is Hims & Hers Health, Inc. a safe investment right now?
Hims & Hers Health, Inc.'s Altman Z-Score of 3.84 places it in the safe zone. Our fair value estimate is $21.20 (Overvalued). Moat rating: 2.3/5 stars.
Could Hims & Hers Health, Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 3.84 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives HIMS's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.1686 | 1.2 | 0.2 |
| B · Retained Earnings / Total Assets | RE / TA | -0.0528 | 1.4 | -0.07 |
| C · EBIT / Total Assets | EBIT / TA | 0.049 | 3.3 | 0.16 |
| D · Market Cap / Total Liabilities | MCap / TL | 4.0975 | 0.6 | 2.46 |
| E · Revenue / Total Assets | Rev / TA | 1.0895 | 1.0 | 1.09 |
How has HIMS's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 72.72 | Safe |
| 2023 | 41.9 | Safe |
| 2024 | 19.38 | Safe |
| 2025 | 3.84 | Safe |
Source: Calculated from HIMS's latest 10-K filing on SEC EDGAR.
What is Hims & Hers Health, Inc. actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $0.53 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $0.51 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $0.55 | 13 analysts consensus |
| Trailing P/E | 56.9x | Current market pricing |
| Fair P/E (β discount) | 40.0x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Growing | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $24.31 (13 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Hims & Hers Health, Inc. have a durable competitive advantage?
Moat rating: 2.3/5.
What makes up HIMS's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 2/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is HIMS's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | -22.0% | — |
| 2023 | -8.6% | Rising |
| 2024 | 13.0% | Rising |
| 2025 | 7.0% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Hims & Hers Health, Inc.'s dividend safe?
Hims & Hers Health, Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $2.3B | $1.5B | $0.5B | Rising |
| Net Income | $0.1B | $0.1B | −$0.1B | Rising |
| Free Cash Flow | $0.1B | $0.2B | −$0.0B | Rising |
| Gross Margin | 73.8% | 79.5% | 77.6% | Stable |
Recent events that affect our HIMS analysis
HIMS earnings report scheduled
Upcoming report. Consensus EPS estimate: $0.14. Revenue estimate: $617.2M. Our current Fair Value: $21.20 — a significant beat or miss could shift this estimate.
HIMS analyst consensus: 20% bullish (3 of 15 analysts)
2 Strong Buy, 1 Buy, 11 Hold, 0 Sell, 1 Strong Sell. Consensus target: $24.31 (16.2% downside). Compare with our independent Fair Value: $21.20.
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS beat EPS estimates by 92.5%
Reported EPS: $0.08 vs estimate $0.04. Earnings strength supports our Fair Value of $21.20 (26.9% below current price).
HIMS filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS missed EPS estimates by 41.0%
Reported EPS: $0.06 vs estimate $0.10. Our Fair Value of $21.20 may face downward pressure if the trend continues.
HIMS filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS beat EPS estimates by 3.2%
Reported EPS: $0.17 vs estimate $0.16. Earnings strength supports our Fair Value of $21.20 (26.9% below current price).
HIMS filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS beat EPS estimates by 65.0%
Reported EPS: $0.20 vs estimate $0.12. Earnings strength supports our Fair Value of $21.20 (26.9% below current price).
HIMS filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
HIMS beat EPS estimates by 0.7%
Reported EPS: $0.11 vs estimate $0.11. Earnings strength supports our Fair Value of $21.20 (26.9% below current price).
HIMS filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
HIMS filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Hims & Hers Health, Inc.
What is Hims & Hers Health, Inc. stock price today?
Hims & Hers Health, Inc. (HIMS) stock price is $29.01 as of the latest market close, traded on the NYSE exchange.
What does Hims & Hers Health, Inc. do?
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. It offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
What is Hims & Hers Health, Inc. market cap?
Hims & Hers Health, Inc. has a market capitalization of $6.61B, classifying it as a mid-cap stock in the Healthcare sector.
What sector and industry is HIMS in?
Hims & Hers Health, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. It trades on the NYSE under the ticker symbol HIMS.
Is HIMS stock overvalued or undervalued?
Based on our valuation model, Hims & Hers Health, Inc. trades 36.8% above our fair value estimate — potentially overvalued.
- FairValueLabs Fair Value: $21.20
- Current Price: $29.01
- Valuation Zone: Overvalued
What is HIMS stock forecast and analyst target price?
Based on 13 Wall Street analysts, the consensus price target for Hims & Hers Health, Inc. is $24.31, implying downside of 16.2% from the current price.
- Analyst High Target: $30.00
- Analyst Low Target: $16.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Hims & Hers Health, Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Hims & Hers Health, Inc.:
- Revenue growth (current year est.): 16.2%
- EPS growth (current year est.): 7.9%
- Revenue growth (next year est.): 17.4%
- EPS growth (next year est.): 21.9%
What are Hims & Hers Health, Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $2.3B | Rising |
| Net Income | $0.1B | Rising |
| Free Cash Flow | $0.1B | Rising |
| Gross Margin | 73.8% | Stable |
What is HIMS's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 56.9x
- Forward P/E (next 12 months est.): 20.4x
- FairValueLabs Fair P/E: 40.0x
How volatile is HIMS stock?
Hims & Hers Health, Inc. has a beta of 2.31, meaning it is significantly more volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc.'s balance sheet shows:
- Total Cash: $577.5M
- Total Debt: $1.12B
- Net Cash Position: $-543.1M
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Hims & Hers Health, Inc.'s free cash flow?
Hims & Hers Health, Inc. generated $110.5M in trailing twelve-month free cash flow (from $300.0M in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Hims & Hers Health, Inc. pay a dividend?
Hims & Hers Health, Inc. does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is Hims & Hers Health, Inc. at risk of going bankrupt?
Hims & Hers Health, Inc.'s Altman Z-Score is 3.84, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Hims & Hers Health, Inc. have a durable competitive advantage?
Hims & Hers Health, Inc. scores 2.3/5 stars (Weak moat) in our moat analysis:
- ROIC Stability: 2/5
- Gross Margin Trend: 2/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is HIMS's return on equity (ROE)?
Hims & Hers Health, Inc.'s return on equity is 25.2%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy HIMS stock?
HIMS shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol HIMS
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is HIMS a value stock or speculative?
FairValueLabs classifies Hims & Hers Health, Inc. as Value-Speculation. It has some value characteristics but carries elevated risk factors that make it speculative. Extra due diligence is recommended.
Who is the CEO of Hims & Hers Health, Inc.?
The current CEO of Hims & Hers Health, Inc. is Mr. Andrew Dudum.
What is HIMS's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $0.51
- Forward EPS (next 12 months est.): $1.42
- Analyst consensus EPS (this year): $0.55
- Analyst consensus EPS (next year): $0.67
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
HIMS analysis methodology: How we calculate fair value, Z-Scores, and moat ratings